Connecting the dots between COVID-19 and neurological disorders

John Connolly and Masataka Nishiga discuss the effects of SARS-CoV-2 on the neurological and cardiovascular systems.

Angela Rasmussen and Ya-Chi Ho explore the positive and negative aspects of the host immune response to SARS-CoV-2 infection and discuss how this knowledge influences therapeutic benefits.

Looking at the future of neurodegeneration research!

Overactive immune cells identified in a mouse model and in postmortem human brain tissue may offer a potential therapeutic target for cognitive delays associated with the condition, researchers report.

The rare complication known as multisystem inflammatory syndrome in children (MIS-C) differs from both Kawasaki disease and severe adult cases of COVID-19, a study finds.

A meta-analysis of seven randomized controlled trials concludes that dexamethasone and other corticosteroids reduce 28-day mortality in seriously ill patients.

A handful of viruses have been associated with long-term, debilitating symptoms in a subset of those who become infected. Early signs hint that SARS-CoV-2 may do the same.

The presence of a particular set of RNAs in the blood forewarns of an onset of severe symptoms and points to the cells involved.